效应器
封锁
糖酵解
癌症研究
下调和上调
CD8型
PD-L1
肿瘤微环境
细胞生物学
免疫检查点
细胞毒性T细胞
生物
免疫疗法
化学
免疫系统
新陈代谢
免疫学
生物化学
肿瘤细胞
受体
基因
体外
作者
Shogo Kumagai,Shohei Koyama,Kota Itahashi,Tokiyoshi Tanegashima,Yi-Tzu Lin,Yosuke Togashi,Takahiro Kamada,Takuma Irie,Genki Okumura,Hidetoshi Kono,Daisuke Ito,Rika Fujii,Sho Watanabe,Atsuo Sai,Shota Fukuoka,Eri Sugiyama,Go Watanabe,Takuya Owari,Hitomi Nishinakamura,Daisuke Sugiyama
出处
期刊:Cancer Cell
[Cell Press]
日期:2022-01-28
卷期号:40 (2): 201-218.e9
被引量:492
标识
DOI:10.1016/j.ccell.2022.01.001
摘要
The balance of programmed death-1 (PD-1)-expressing CD8+ T cells and regulatory T (Treg) cells in the tumor microenvironment (TME) determines the clinical efficacy of PD-1 blockade therapy through the competition of their reactivation. However, factors that determine this balance remain unknown. Here, we show that Treg cells gain higher PD-1 expression than effector T cells in highly glycolytic tumors, including MYC-amplified tumors and liver tumors. Under low-glucose environments via glucose consumption by tumor cells, Treg cells actively absorbed lactic acid (LA) through monocarboxylate transporter 1 (MCT1), promoting NFAT1 translocation into the nucleus, thereby enhancing the expression of PD-1, whereas PD-1 expression by effector T cells was dampened. PD-1 blockade invigorated the PD-1-expressing Treg cells, resulting in treatment failure. We propose that LA in the highly glycolytic TME is an active checkpoint for the function of Treg cells in the TME via upregulation of PD-1 expression.
科研通智能强力驱动
Strongly Powered by AbleSci AI